Drug monitoring guidelines
Variations in monitoring requirements may occur and this should be read in conjunction with:
- medication specific information provided by the rheumatology unit
- manufacturer's data sheet.
If you have any concerns or queries regarding your patient's blood monitoring, please contact us.
If you advise a patient to withhold medication, please let us know for our records:
Contact us
For details of standard drug monitoring for patients on long-term treatment please refer to:
BOB ICS Shared Care Guidelines 'Rheumatology Monitoring General Guidance'.
For specific advice on methotrexate use please see:
Paediatric and adolescent guidance - British Society for Rheumatology
For information on monitoring of biologics in children and adolescents please see:
Oxford Academic Rheumatology - British Society for Rheumatology
